Biomunex Announces the Upcoming Start of Clinical Development of IPN60330, the First MAIT Engager, a New Therapeutic Class in Oncology, Following the Completion of the FDA Review Period

Posted on by sHq_LoGiNz

PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biomunex announces the upcoming start of clinical development of IPN60330, the first MAIT engager, a new therapeutic class in oncology

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.